Inhibition of Hedgehog Signaling Reduces the Side Population in Human Malignant Mesothelioma Cell Lines
Researchers evaluated the potential anticancer effects of cyclopamine, a chemical inhibitor of hedgehog signaling, in human malignant mesothelioma (HMM) cell lines. Treatment of HMM cells with cyclopamine significantly reduced the abundance of side population cells, which were measured using an assay composed of Hoechst 33342 dye staining and subsequent flow cytometry. [Cancer Gene Ther]
Full Article
REVIEWS
Metformin and Prostate Cancer Stem Cells: A Novel Therapeutic Target
The authors explore the characteristics of prostate cancer stem cells (CSCs), their role in tumor propagation and therapeutic resistance and the role of metformin as a potential prostate CSC sensitizer to current anticancer therapies. [Prostate Cancer Prostatic Dis] Abstract
OncoMed Initiates Phase I Clinical Trial for Anti-RSPO3 Antibody
OncoMed Pharmaceuticals, Inc. announced dosing of the first patient in its anti-RSPO3 antibody Phase Ia/Ib clinical trial. Anti-RSPO3 is the first drug in its class to target the R-spondin-LGR pathway, an important cancer stem cell pathway identified by OncoMed researchers. [OncoMed Pharmaceuticals, Inc.] Press Release
CDRD & OICR Team up to Advance Cutting-Edge New Cancer Treatments
Two of Canada’s leading drug research and commercialization centers have announced a call for proposals to help bring new cancer treatments to patients through collaborative technology-development projects from academic investigators across Canada. [Center for Drug Research and Development (CDRD)] Press Release
Recruit Top Talent:
Reach more than 60,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!